The Longevity Stack: What the Science Actually Says About Fatty15 (C15:0) and TruNiagen (NR)
Two of the most scientifically compelling supplements in the aging space - and why they may work better together
If you spend any time in longevity circles, you’ve encountered the NAD+ conversation. And increasingly, you’re hearing about a strange, previously ignored saturated fatty acid called C15:0. The supplement world is awash with hype, so this post cuts through the noise and examines what peer-reviewed science actually says about TruNiagen (a clinically studied form of nicotinamide riboside, or NR) and Fatty15 (a pure C15:0 supplement) - and why the combination, while not yet directly tested in a clinical trial, has a compelling mechanistic rationale.
A few caveats upfront: this is not medical advice, and the science on both compounds is still maturing. But the evidence base for each is unusually strong by supplement standards, and the potential synergies are worth understanding.
Part I: The NAD+ Crisis in Your Cells
What Is NAD+, and Why Does It Decline?
Nicotinamide adenine dinucleotide (NAD+) is arguably the most important coenzyme in your body. It sits at the crossroads of energy metabolism, DNA repair, and longevity signaling - serving as a co-substrate for enzymes including the sirtuins (SIRT1–7) and poly-ADP-ribose polymerases (PARPs), both of which are critical regulators of cellular health and stress response.
The problem is that NAD+ levels fall dramatically with age. By some estimates, blood NAD+ in a 60-year-old is roughly half what it was at 20 [1]. This decline has been directly implicated in the hallmarks of aging - impaired mitochondrial function, accumulating DNA damage, dysregulated inflammation, and cellular senescence [2]. Age-associated NAD+ depletion has been specifically linked to metabolic, cardiovascular, and neurodegenerative disorders [1].
The sirtuin connection is especially important. Sirtuins are NAD+-dependent enzymes that regulate everything from gene expression and metabolic homeostasis to inflammation suppression. When NAD+ drops, sirtuin activity falls with it, leading to impaired regulatory control over inflammation and deficient DNA repair responses [10]. Restoring NAD+ is therefore not a narrow biochemical intervention — it’s an attempt to re-engage some of the body’s core aging-defense systems.
Enter Nicotinamide Riboside (NR)
NR is a form of vitamin B3 that serves as a direct precursor to NAD+. Unlike niacin (which causes flushing) or nicotinamide (which can inhibit sirtuins at high doses), NR has a favorable safety and tolerability profile at doses up to 2,000 mg/day in humans.
TruNiagen is ChromaDex’s trademarked NR product (NIAGEN), and it is the most clinically studied commercial NR formulation available. In an 8-week, randomized, double-blind, placebo-controlled trial, NR supplementation at doses of 100, 300, and 1,000 mg dose-dependently and significantly increased whole blood NAD+ levels by 22%, 51%, and 142% respectively, with increases maintained throughout the study - and with no reports of flushing and no significant adverse events [3].
Part II: What TruNiagen Actually Does in Humans
Muscle Mitochondria and Biogenesis
One of the more rigorous NR trials to date examined 20 BMI-discordant monozygotic twin pairs supplemented with escalating doses of NR (250 to 1,000 mg/day) for five months [28]. This design elegantly controls for genetic variation. Results showed that NR improved systemic NAD+ metabolism, increased muscle mitochondrial number (mitochondria became roughly 14% more abundant in type I muscle fibers [30]), improved myoblast differentiation, and favorably altered gut microbiota composition -in both the leaner and heavier co-twins. NR also modulated epigenetic control of gene expression in muscle and adipose tissue. Body composition and standard metabolic markers did not improve, reinforcing the idea that NR’s primary benefits are in the realm of cellular and mitochondrial health rather than rapid metabolic rescue.
Walking Distance in Peripheral Artery Disease
A randomized, double-blind clinical trial published in Nature Communications enrolled 90 people with peripheral artery disease (PAD) - a population with significant mitochondrial dysfunction in skeletal muscle [32]. After six months of NR supplementation, participants improved their 6-minute walk distance by +7.0 meters compared to −10.6 meters in the placebo group. Among those who took at least 75% of their pills, the improvement was 31.0 meters. This is a clinically meaningful functional outcome in a high-risk aging population, and it aligns with the known mechanisms: NAD+ activating SIRT1, improving mitochondrial activity, and enhancing nitric-oxide-mediated endothelial function.
Cognition and Neurodegeneration
A 2025 crossover, double-blind, randomized placebo-controlled trial conducted at Massachusetts General Hospital tested NR (TruNiagen, 1 g/day) for 8 weeks in older adults with subjective cognitive decline and mild cognitive impairment [1]. The trial examined both cognitive performance and plasma Alzheimer’s disease biomarkers - establishing NR as a candidate therapeutic avenue against neurodegenerative pathologies in aging populations, where NAD+ depletion plays an established mechanistic role.
Accelerated Aging Syndromes
Perhaps the most striking recent NR trial came from Chiba University, Japan, published in Aging Cell in June 2025 [5]. Researchers conducted the world’s first rigorous clinical trial of NR in patients with Werner syndrome - a rare hereditary progeroid (accelerated aging) syndrome causing early mortality. The results showed NR improved arterial stiffness (cardio-ankle vascular index) and reduced skin ulcer area, with a trend toward mitigating heel pad thinning. This landmark trial is significant not just for Werner syndrome but as a proof-of-concept for NAD+ restoration in accelerated biological aging.
Inflammation: The SIRT2 Connection
A 2025 study published in Aging Cell from UC Berkeley demonstrated that SIRT2, an NAD+-dependent deacetylase, suppresses multiple immune pathways that become activated during aging [11]. Boosting NAD+ via supplementation reactivates SIRT2-mediated suppression of aging-associated inflammation - across multiple immune pathways simultaneously. This makes NAD+ restoration an unusually broad anti-inflammatory strategy, not targeted at a single cytokine but at the upstream regulatory machinery.
You’ve reached the subscriber section
This article continues with the parts that matter most.
The free section covered the biology. What’s behind the paywall is where it gets practical - the combination rationale, exact dosing protocols, timing guidance, who actually benefits, and an honest breakdown of what the science still can’t tell us.
✓ Why C15:0 and NR may work better together - the mechanism explained ✓ Exact doses, timing, and how to take both supplements correctly ✓ Who benefits most - and who should wait for more evidence ✓ An honest verdict on the gaps - what the science can’t yet confirm
